This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The Proteomics Core in the COBRE Center for Cancer Research Development (CCRD) at Rhode Island Hospital was established in September 2002 as part of the COBRE grant. The Core is currently offering LC-MS/MS and SELDI-TOF protein identification, biomarker identification with LC-MS/MS and SELDI-TOF mass spectrometry and 2-D electrophoresis, and chromatographic and 1- and 2-D electrophoretic separations and analysis of proteins and peptides as a service for four Rhode Island COBRE Centers, Rhode Island Hospital and other Lifespan Hospitals, Brown University and other neighboring institutions. Proteomics Core serves the following functions: 1) Identification of proteins isolated by 1- and 2-D gel electrophoresis, western blotting or chromatography. 2) Differential analysis and identification and relative quantification of up- or down-regulated proteins between two different samples with LC-MS/MS, SELDI-TOF MS and/or 2-D electrophoresis. 3) Study of protein-protein and protein-ligand interaction by use of liquid chromatography, SELDI-TOF MS and immunochemical methods combined with analyses with 1- and 2-D electrophoresis. 4) Isolation and identification of proteins associated in complexes to elucidate their biological function. 5) Identification and mapping of post-translation modifications and processing of target proteins. This renewal application describes: A) Specific Aim; B) History of the Proteomics Core facility, current instrumentation and operational plan for the facility; C) Core Progress including the role of the Proteomics Core had in fulfilling research objectives in COBRE-funded, NIH-funded and other research programs in Greater Providence and Rhode Island;Publications and other highlights; D) Experimental plan ?to research the method development and identification of biomarkers for cancer and other diseases as well as plans and activities to obtain additional funding for the facility.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
Exploratory Grants (P20)
Project #
5P20RR017695-07
Application #
8167901
Study Section
Special Emphasis Panel (ZRR1-RI-B (01))
Project Start
2010-05-01
Project End
2011-04-30
Budget Start
2010-05-01
Budget End
2011-04-30
Support Year
7
Fiscal Year
2010
Total Cost
$530,328
Indirect Cost
Name
Rhode Island Hospital
Department
Type
DUNS #
075710996
City
Providence
State
RI
Country
United States
Zip Code
02903
Šrajer Gajdošik, Martina; Hixson, Douglas C; Brilliant, Kate E et al. (2018) Soft agar-based selection of spontaneously transformed rat prostate epithelial cells with highly tumorigenic characteristics. Exp Mol Pathol 105:89-97
Lopez, Chelsea E; Sheehan, Hannah C; Vierra, David A et al. (2017) Proteomic responses to elevated ocean temperature in ovaries of the ascidian Ciona intestinalis. Biol Open 6:943-955
Francois-Vaughan, Heather; Adebayo, Adeola O; Brilliant, Kate E et al. (2016) Persistent effect of mTOR inhibition on preneoplastic foci progression and gene expression in a rat model of hepatocellular carcinoma. Carcinogenesis 37:408-419
Li, Ming; Tucker, Lynne D; Asara, John M et al. (2016) Stem-loop binding protein is a multifaceted cellular regulator of HIV-1 replication. J Clin Invest 126:3117-29
Breen, Lucas D; Pu?i?-Bakovi?, Maja; Vu?kovi?, Frano et al. (2016) IgG and IgM glycosylation patterns in patients undergoing image-guided tumor ablation. Biochim Biophys Acta 1860:1786-94
Mulvey, Hillary E; Chang, Audrey; Adler, Jason et al. (2015) Extracellular vesicle-mediated phenotype switching in malignant and non-malignant colon cells. BMC Cancer 15:571
Cheng, Yan; Holloway, Michael P; Nguyen, Kevin et al. (2014) XPO1 (CRM1) inhibition represses STAT3 activation to drive a survivin-dependent oncogenic switch in triple-negative breast cancer. Mol Cancer Ther 13:675-86
Yousuf, Saad; Duan, MeiLi; Moen, Erika L et al. (2014) Raf kinase inhibitor protein (RKIP) blocks signal transducer and activator of transcription 3 (STAT3) activation in breast and prostate cancer. PLoS One 9:e92478
Cao, Weibiao; Tian, Wei; Hong, Jie et al. (2013) Expression of bile acid receptor TGR5 in gastric adenocarcinoma. Am J Physiol Gastrointest Liver Physiol 304:G322-7
Panagopoulos, Kiriaki; Cross-Knorr, Sam; Dillard, Christen et al. (2013) Reversal of chemosensitivity and induction of cell malignancy of a non-malignant prostate cancer cell line upon extracellular vesicle exposure. Mol Cancer 12:118

Showing the most recent 10 out of 127 publications